Osi 906

Manufactured by Chemietek

The OSI-906 is a laboratory instrument designed for the detection and quantification of analytes in various samples. It utilizes a specific measurement technique to provide accurate and reliable data. The core function of the OSI-906 is to facilitate the analysis of samples in a laboratory setting.

Automatically generated - may contain errors

Lab products found in correlation

7 protocols using osi 906

Characterization of Kinase Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

BMS-754807, OSI-906, and GSK1838705A were obtained from Chemie Tek. MK-2206 and PF-4708671 were purchased from Selleckchem. U0126 was purchased from MedChemExpress. All drugs were dissolved in DMSO at a proper concentration and stored at −20 °C.

Wang Q., Zhang Y., Zhu J., Zheng H., Chen S., Chen L, & Yang H.S. (2020). IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas. Signal Transduction and Targeted Therapy, 5, 153.

+ Open protocol

+ Expand

Ligands and Inhibitors for Cell Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Des[1–3]IGF-1 and recombinant human epidermal growth factor (EGF) were obtained from Cell Sciences (Canton, MA). alamarBlue, Dulbecco modified Eagle’s medium (DMEM)/F-12 media with HEPES, Roswell Park Memorial Institute (RPMI) 1640 media, and fetal bovine serum were obtained from Invitrogen (Carlsbad, CA). Hydrocortisone was purchased from Sigma–Aldrich (St. Louis, MO). OSI-906 and BMS754807 were obtained from Chemietek (Indianapolis, IN). Gefitinib, lapatinib, crizotinib, and cederanib were obtained from LC Laboratories (Woburn, MA). Dasatinib, BMS599626, NVP-BEZ235, PF-04691502, XL-147, MKK2206, GSK690693, temsirolimus, AT7867, foretinib, panobinostat, SAHA, diclofenac, serdemetan, and YM-155 were obtained from Selleck Chemicals (Houston, TX). PF-4708671 was obtained from Santa Cruz Biotechnology (Dallas, TX). PP242 was kindly provided by Dr. Michael Harding (University of Virginia, Charlottesville, VA). Anti-IGF-1Rβ, anti-AKT, anti-pAKT (S473), anti-pAKT (T308), anti-EGFR, and anti-pEGFR, were obtained from Cell Signaling Technology (Beverly, MA). Anti-pIGF-1R/pIR (Y1158/Y1162/Y1163) was obtained from Millipore (Bill-erica, MA).

Axelrod M.J., Mendez R.E., Khalil A., Leimgruber S.S., Sharlow E.R., Capaldo B., Conaway M., Gioeli D.G., Weber M.J, & Jameson M.J. (2015). Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways. Head & neck, 37(12), 1722-1732.

+ Open protocol

+ Expand

Inhibition of Tyrosine Kinase Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Small molecule tyrosine kinase inhibitor OSI-906 was obtained from Chemietek (Indianapolis, IN). Puromycin and doxycycline were purchased from Sigma-Aldrich (St. Louis, MO).

Leiphrakpam P.D., Lazenby A.J., Chowdhury S., Smith L.M., Mathiesen M., Brattain M.G., Wang J., Black J.D, & Are C. (2019). Prognostic and therapeutic implications of NHERF1 expression and regulation in colorectal cancer. Journal of surgical oncology, 121(3), 547-560.

+ Open protocol

+ Expand

Inhibiting IGF-1 Signaling and Assessing Cell Viability

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were treated with NVP-AEW541 (Cayman Chemical) and OSI-906 (ChemieTek) at the indicated concentrations. Prior to treatment with IGF-1, cells were kept in serum-free media for two hours in combination with the IGF-1 inhibitor. Cells were then treated with IGF-1 (Cell Signaling Technologies) for 15 min and lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 0.1% SDS) supplemented with 200 mM NaVO₄ and 50 mM NaF. Cell extracts were separated by SDS-PAGE and blotted with anti-phospho AKT and imaged (LiCor). For assessment of cell viability, EWS502 cells were transduced with lentiviral pLL5.0-PTEN or pLL5.0 as a vector control. 24 hours post infection the cells were treated with NVP-AEW541 in complete media. Viability was assayed 72 hours following NVP-AEW541 treatment using WST-1 (Roche).

Patel M., Gomez N.C., McFadden A.W., Moats-Staats B.M., Wu S., Rojas A., Sapp T., Simon J.M., Smith S.V., Kaiser-Rogers K, & Davis I.J. (2014). PTEN deficiency mediates a reciprocal response to IGF-1 and mTOR inhibition. Molecular cancer research : MCR, 12(11), 1610-1620.

+ Open protocol

+ Expand

Mab Specification and Reagents Used

Check if the same lab product or an alternative is used in the 5 most similar protocols

A specification of mAb used in this study is shown in Table 1. The ErbB-targeting drugs canertinib, BIBW2992, and BMS-599626, the KIT kinase blockers nilotinib, midostaurin (PKC412) and dasatinib, and the insulin-like growth factor-1 receptor (IGF-1-R) blocker OSI-906, were from Chemietek (Indianapolis, IN). The irreversible ErbB inhibitor pelitinib and the CD33-targeting antibody-conjugate gemtuzumab ozogamicin (mylotarg) were kindly provided by Wyeth (Cambridge, MA). Recombinant human (rh) stem cell factor (SCF) was purchased from Peprotech (Rocky Hill, NJ), rh erythropoietin (EPO) and rh transforming growth factor-β1 (TGF-β1) from R&D Systems (Minneapolis, MN), and rh Heregulin-α (EGF-domain) from Sigma-Aldrich (St. Louis, MO). Dulbecco's modified eagle medium (DMEM) and fetal calf serum (FCS) were from Gibco Life Technologies (Gaithersburg, MD).

Mirkina I., Hadzijusufovic E., Krepler C., Mikula M., Mechtcheriakova D., Strommer S., Stella A., Jensen-Jarolim E., Höller C., Wacheck V., Pehamberger H, & Valent P. (2014). Phenotyping of Human Melanoma Cells Reveals a Unique Composition of Receptor Targets and a Subpopulation Co-Expressing ErbB4, EPO-R and NGF-R. PLoS ONE, 9(1), e84417.

+ Open protocol

+ Expand

Cell Line Culture and Compound Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols

All cell lines were provided and authenticated by The Center of Molecular Therapeutics (Massachusetts General Hospital Cancer Center) and cultured in RPMI medium containing 5% fetal bovine serum (FBS), except for YAPC, HPAC, HPAF-II, and Panc1, which were grown in DMEM with 10% FBS, and MIA-PaCa-2, which was grown in DMEM/F12 with 5% FBS. Cell media were supplemented with penicillin/streptavidin and glutamine, and cells were maintained at 37 °C and 5% CO₂. BMS-754807, OSI-906, and PD-0332991 were purchased from ChemieTek, temsirolimus and AZD8055 were from Selleck Chemicals. The compounds used to treat cells were dissolved in DMSO at 10 mM and stored at -80 °C.

Heilmann A.M., Perera R.M., Ecker V., Nicolay B.N., Bardeesy N., Benes C.H, & Dyson N.J. (2014). CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer research, 74(14), 3947-3958.

+ Open protocol

+ Expand

Drug Preparation and Storage Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

OSI-906 and BMS-754807 were purchased from Chemie Tek (Indianapolis, IN). PF-4708671 was obtained from Selleckchem (Houston, TX). All drugs were dissolved in DMSO at 10 mmol/L and stored at −20°C for in vitro studies. For in vivo studies, both OSI-906 and PF-4708671 were dissolved in 25 mmol/L tartaric acid.

Zhang Y., Wang Q., Chen L, & Yang H.S. (2015). Inhibition of p70S6K1 activation by Pdcd4 overcomes the resistance to an IGF-1R/IR inhibitor in colon carcinoma cells. Molecular cancer therapeutics, 14(3), 799-809.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!